Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
16.87
-0.12 (-0.71%)
At close: Dec 26, 2025, 4:00 PM EST
16.88
+0.01 (0.06%)
After-hours: Dec 26, 2025, 7:32 PM EST
Denali Therapeutics Employees
Denali Therapeutics had 422 employees as of December 31, 2024. The number of employees decreased by 23 or -5.17% compared to the previous year.
Employees
422
Change (1Y)
-23
Growth (1Y)
-5.17%
Revenue / Employee
n/a
Profits / Employee
-$1,181,858
Market Cap
2.63B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 422 | -23 | -5.17% |
| Dec 31, 2023 | 445 | 18 | 4.22% |
| Dec 31, 2022 | 427 | 47 | 12.37% |
| Dec 31, 2021 | 380 | 89 | 30.58% |
| Dec 31, 2020 | 291 | 30 | 11.49% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DNLI News
- 18 days ago - Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment - Seeking Alpha
- 18 days ago - Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 19 days ago - Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 23 days ago - Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript - Seeking Alpha
- 24 days ago - Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement - GlobeNewsWire
- 26 days ago - Denali: Regulatory Delay Is A Strategic Opportunity - Seeking Alpha
- 5 weeks ago - Denali Therapeutics Inc. (DNLI) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 7 weeks ago - Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire